BYLINE: CHRISTEN BROWNLEE
At a glance:
- A new AI model called COMPASS uses tumor gene expression data to predict which patients will respond to cancer immunotherapy drugs called immune checkpoint inhibitors.
- Analyzing past data from 16 clinical cohorts, COMPASS predicted ICI response 8.5 percent more accurately than the best existing approach.
- If validated in clinical trials, the tool could lead to better precision medicine and cancer drug development.
Newswise — Cancer immunotherapy drugs known as immune checkpoint inhibitors (ICIs) can be miracle drugs for cancer patients, curing some and turning deadly disease into a manageable chronic condition in others. But these drugs work for only a subset of patients, with few indications why — a knowledge gap that has detrimental effects on patient prognosis, clinical trial recruitment, and research that could lead to new therapies.
Continue reading “AI Tool Will Help Improve Cancer Treatment”







